Navigation Links
ConvaTec Healthcare Announces Plans to Refinance Secured Term Loans
Date:3/3/2011

SKILLMAN, N.J., March 3, 2011 /PRNewswire/ -- ConvaTec Healthcare, a world-leading developer, manufacturer and marketer of innovative medical technologies for community and hospital care, today announced that, recognizing favorable conditions in the credit markets, it is exploring the option to refinance all or a portion of its senior secured term loans originally entered into on December 22, 2010.

While the year-end audit process is ongoing, ConvaTec presently expects adjusted EBITDA for the year ended December 31, 2010 to be within a range of approximately $425-435mm, although this view is based on a number of assumptions and estimates. ConvaTec management cautions that the foregoing information has not been audited or reviewed by the company's independent auditors and should not be regarded as a representation or forecast by ConvaTec or any other person affiliated with the company regarding the results that will be reported for the year ended December 31, 2010.

About ConvaTecConvaTec is a leading developer and marketer of innovative medical technologies. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New Jersey, the company conducts business in over 100 countries, serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are all statements other than statements of historical facts.  Certain of these forward looking statements are identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should," or "will" or the negative of such terms or other comparable terminology.  Others can be identified from the context in which the statements are made.  These statements involve a number of risks and uncertainties.  Any forward-looking statements that we make herein and in future reports and statements are not guarantees of future performance, and actual results may differ materially from those in such forward-looking statements as a result of various factors relating to our strategy, outlook and growth prospects, including our operational and financial targets; the expected growth of the markets in which we operate; the competitive environment in which we operate; the economic outlook in general and, in particular, economic conditions in the European and U.S. markets; growth in demand for our products, increases in the penetration of our products into their respective markets, reimbursement rates for our products, or similar measures; and our expansion plans, including planned expansion into and growth in emerging markets; our ability to gain necessary regulatory approvals and desirable reimbursement rates for our newly developed products and technologies; and our ability to market and launch attractive new product designs and technologies.  All forward-looking statements made in this press release are made as of the date hereof, and the risk that actual results will differ materially from expectations expressed herein will increase with the passage of time.  The Company undertakes no duty to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

This announcement is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) (a) to (d)  of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This document is an advertisement for purposes of applicable measures implementing Directive 2003/71/EC.

This announcement is not an offer to sell or the solicitation of an offer to buy the new notes in any jurisdiction in which such an offer, solicitation or sale would be unlawful.Media ContactNimisha Savani908-904-2522Nimisha.savani@convatec.com
'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ConvaTec Announces New Appointment to Leadership Team
2. ConvaTec Announces New Appointments to Leadership Team
3. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
4. Bradford Barton Named President, ConvaTec U.S.
5. ConvaTec to Present at AdvaMed 2010: The MedTech Conference
6. ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing
7. New Data Supports ConvaTec Negative Pressure Wound Therapy
8. Zimmer Holdings to Present at Barclays Capital 2011 Global Healthcare Conference
9. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
10. Berg Biosystems and GNS Healthcare Announce Joint Venture - MAP Biosystems
11. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):